Abstract: Provided is a method for solubilizing cellulose in which cellulose can be solubilized in a short period of time with a low amount of excess decomposition and without the use of a catalyst or other chemicals. A starting material containing cellulose is pulverized to reduce the crystallization thereof, adjusted for moisture content, reacted with water in the absence of a catalyst, and converted into a water-soluble component. At this point, the reaction is performed at a temperature of 100° C. or more and less than 300° C., and a total pressure of 0.05 MPa or more and less than 10 MPa. Water is added and extracted from the water soluble component, and solid-liquid separation is performed to separate the solids and the aqueous solution.

Abstract: A chitosan solution is formed from chitin, which is a homopolymer of beta (1-4)-linked N-acetyl-D-glucosamine. Rinsed, dried and ground chitin undergoes a process of deacetylation to convert some N-acetyl glucosamine to glucosamine, a primary component of chitosan. The chitosan solution is prepared by mixing 5chitosan with an alpha-hydroxy acid such as glycolic acid. An aqueous chelated silver solution is prepared by mixing silver oxide with a carboxylic acid such as citric acid. The chitosan solution can then be mixed with the silver solution resulting in a cationic complex. The cationic complex of the present invention may then be electrostatically bonded with generally negatively charged surfaces. In use, citrate promotes uptake of the silver by microbes. The antimicrobial complex can be applied via several methods of application, including an impregnated wipe, a foam, a gel, a spray, a lotion and an ointment.

Abstract: The invention relates to composition comprising a dextran-tyramine conjugate and a conjugate selected from the group consisting of chondroitin sulphate-tyramine, collagen-tyramine, chitosan-tyramine, chitosan-phloretic acid, gelatine-tyramine, heparan sulphate-tyramine, keratin sulphate-tyramine, hyaluronic acid-tyramine and heparin-tyramine.

Abstract: The present invention relates to novel compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof that are useful in the treatment and/or prevention of human and animal bacterial infections and associated diseases and conditions; compositions containing such compounds; derivation of such compounds by fermentation and isolation, partial synthesis and total synthesis; methods of inhibiting bacterial growth; methods of treating, preventing or controlling bacterial infection; biologically pure cultures of bacterial strains from which such compounds may be produced; and processes for preparing compositions containing such compounds.

Abstract: The present invention provides a process for producing silylated pullulan, which features reacting pullulan with N,O-bistrimethylsilylacetamide by using, as a reaction medium, only one of N-methyl-2-pyrrolidone and N-ethyl-2-pyrrolidone or a mixed solvent of both of them. Compared with conventional processes, the process according to the present invention can produce high-purity silylated pullulan simply, easily and efficiency.

Abstract: The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of spinocerebellar ataxia (SCA).

Abstract: The present invention provides gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO2, N2O, and CH4) to induce phase transform with ease.

Abstract: The invention provides a series of novel Lipid A analogs that are structually simple, synthetically accessible, and capable of blocking the cellular receptor within the signal transduction pathway. The novel Lipid A analogs can include a monosaccharide core with hydrophobic side chains and amino acid ionic motif. The invention further provides methods of using the compounds and compositions thereof in various therapeutic methods.

Abstract: The present disclosure provides a method for the synthesis of IB-MECA. More specifically, the present disclosure provides a simple and high yield method for Good Manufacturing Production (GMP) of IB-MECA. The method involves the reaction of 6-halopurine-9-riboside with a diol protecting reagent; oxidation of the primary alcohol in the diol protected 6-halopurine-9-riboside with a diol protecting reagent; oxidation of the primary alcohol in the diol protected 6-halopurine; reaction of the diol protected 6-halopurine with a nucleophile (e.g. methylamine); substitution of the halogen group with iodobenzylamine and removal of the diol protecting group.

Abstract: The present invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in a human being, comprising four active principles selected as being: a non-nucleoside inhibitor of reverse transcriptase (NNRTI) selected from nevirapine, efavirenz and etravirine; a nucleoside inhibitor of reverse transcriptase (NRTI) selected from lamivudine and emtricitabine; and two different nucleoside or nucleotide inhibitors of reverse transcriptase (NRTI) selected from didanosine, abacavir and tenofovir.

Abstract: The invention relates to amphiphilic C-glycoside derivatives, to methods of using them and to processes for synthesizing them. Specifically, the invention relates to novel cyclic and linear enone-glycolipids and cyclic ketone-glycolipids.

Abstract: The present invention relates to a Rehmannia glutinasa Libosch. extract for reducing blood glucose and lipid levels and treating hematologic diseases such as leukemia, and methods for preparing the same. The extract is prepared by subjecting fresh Rehmannia glutinasa Libosch. to flux extraction, concentrating the resultant extract, dissolving the concentrated extract with water, loading the obtained solution on a column packed with macroporous adsorption resins, eluting the column with ethanol, concentrating and drying the eluate. The extract can be made into clinically acceptable forms of dosage by pharmaceutically conventional measures, including capsule, tablet, pill, granule, dropping pill and so on. The extract is stable and has catalpol content up to 90-98%. The preparing method is simple to operate and applicable to industrial-scale production.

Abstract: The present invention provides intravenous compositions of trehalose for the treatment of signs and symptoms of oculopharyngeal muscular dystrophy (OPMD).

Abstract: A method for producing a diester of polyhydric alcohol and fatty acid, comprising a step of reacting a monoester of polyhydric alcohol and fatty acid in the presence of a catalyst containing a hydrotalcite compound to obtain a diester of polyhydric alcohol and fatty acid.

Abstract: A composition for external use capable of more efficiently deriving the effect of purine substances (and/or salts thereof) including (A) sugar; and (B) at least one member selected from the group consisting of purine substances and salts thereof.

Abstract: Disclosed is a composition comprising ligustroflavone, rhoifolin and hyperin, which is prepared according to rational weight ratio: 40% to 80% ligustroflavone, 5% to 45% rhoifolin and 1% to 40% hyperin. The composition can be used as a neuraminidase inhibitor for preventing and treating influenza, and can be formulated into pharmaceutically acceptable dosage forms.

Abstract: Suggested is a method for improving the yield during the production of crystalline alpha lactose, wherein (a) an aqueous lactose solution is adjusted to a temperature of between about 62 and 67° C., (b) the solution is cooled down to between about 20 and 30° C., (c) the solution is held at this temperature for 0 to 5 h, (d) subsequently, the solution is re-heated to between about 30 and 35° C., (e) the solution is held at this temperature for 0 to 5 h, (f) then the solution is cooled down to about 10° C. and (g) subsequently, the precipitated alpha lactose crystals are separated from the second mother liquor, (h) an amount of a carbohydrate compound is added to the second mother liquor such that the solubility product of the residual amount of lactose that is still soluble is exceeded, (i) the second amount of precipitated alpha lactose crystals is separated from the mother liquor, dried, and (j) both amounts of alpha lactose crystals are combined.

Abstract: A method for producing a polyphenol composition including a step of subjecting (A) a hardly water-soluble polyphenol and (B) one or more selected from cathechins, chlorogenic acids and methylated compounds of hardly water-soluble polyphenols to a heat treatment at from 100 to 180° C. in the presence of an aqueous medium.

Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.

Abstract: The present invention regards a novel administration form and a novel administration regime useful in the treatment and prevention of a bacterial lung infection in patient in need thereof, in particular by providing a composition useful for aerosolization of a highly concentrated solution of aminoglycosides such as Tobramycin.